1 Dalian Key Laboratory of Chronic Disease Research Center, Dalian University, Dalian, Liaoning, China 2 Tangshan Seventh Hospital, Tangshan, Hebei, China Alcoholic liver fibrosis (ALF) developed from ...

In summary, FGF21 exerts multifaceted therapeutic effects on wound healing through the modulation of multiple signaling pathways, including Nrf2-NF-κB, JNK, and SIRT1-mediated mechanisms ... A novel ...

By leveraging siRNA technology to treat disease fundamentally, RN1871 achieves sustained efficacy with less dosing frequency. We look forward to bringing this innovative therapy to hypertension ...

Eli Lilly has recently announced several developments, including positive Phase 2 results for their siRNA therapy lepodisiran and the expansion of their digital healthcare platform, LillyDirect ...

Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA ...

The US biotech has just reported phase 2 trial results with the small, interfering RNA (siRNA) gene-silencing drug showing that it an cause a 90% or greater reduction in Lp(a) levels – a risk ...

NEW YORK – Silexion Therapeutics on Friday revealed plans to clinically develop its siRNA candidate SIL204 as a treatment for KRAS-driven pancreatic cancer. The firm said recent preclinical studies of ...

The study presents valuable findings on the role of Aff3ir, a gene implicated in flow-induced atherosclerosis and regulating the inflammation-associated transcription factor, IRF5. The in vivo data ...

The study, “Edaravone mitigates TDP-43 mislocalization in human amyotrophic lateral sclerosis neurons with potential implication of the SIRT1-XBP1 pathway,” was published in Free Radical Biology and ...